Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 6/20 | 0.58 |
| ▸ | PYGL | P06737 | 5/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2271217 | 0.92 | PYGM (0.61) | PYGMPYGLL3MBTL1MEN1PKM | |
| SCHEMBL2269721 | 0.91 | PYGM (0.58) | PYGMPYGLHDAC1LMNASMN1; SMN2 | |
| SCHEMBL2291520 | 0.88 | SMN1; SMN2 (0.57) | LMNASMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL2274811 | 0.87 | PYGM (0.57) | PYGMPYGLLMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL2269635 | 0.86 | PYGM (0.56) | PYGMPYGLLMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL2270688 | 0.86 | PYGM (0.58) | PYGMPYGLL3MBTL1MEN1PKM | |
| SCHEMBL2275435 | 0.85 | PYGM (0.56) | PYGMPYGLHDAC1MEN1PKM | |
| SCHEMBL2269555 | 0.84 | HPSE (0.55) | PYGMPYGLMEN1PKMKMT2A | |
| SCHEMBL2271524 | 0.83 | PYGM (0.56) | PYGMPYGLSMN1; SMN2MEN1PKM | |
| SCHEMBL2273634 | 0.83 | SERPINE1 (0.60) | PYGMPYGLLMNASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | PYGM 1299/4885PYGL 1834/4885HDAC1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.